Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT

A Clinical Trial to Study the Effects of Two Different Duration of Same Drug Albendazole in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Scan Head at the End of 6 Months

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02243644

Enrollment

Registered

2014-09-18

Start date

2014-03-31

Completion date

2015-10-31

Last updated

2016-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocysticercosis

Keywords

parenchymal neurocysticercosis upto five lesions

Brief summary

Comparing the effect of two different duration of same drug albendazole in patients with Neurocysticercosis less than or equal to 5 lesions on CT head at the end of 6 months.

Detailed description

The trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calcification of cyst on CT head at the end of 6 months after starting albendazole

Interventions

DRUG7 days of albendazole 15 mg/kg/day

group A will receive 7 days of oral albendazole 15 mg/kg/day

DRUG28 days of albendazole 15 mg/kg/day

group B will receive 28 days of oral albendazole 15 mg/kg/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Age 2-18 years. * Number of parenchymal lesions: upto 5\* * Stages of cysticerci at which albendazole treatment is effective * Vesicular stage * Colloid vesicular stage * Granular nodular stage

Exclusion criteria

* Cysticercotic encephalitis * Calcified cyst * Hydrocephalus * Intraventricular cyst * Subarachnoid cyst * Ophthalmic Cysticercosis * No of cysts \>5 * Known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions . * Features of raised ICT (papilloedema, hyperventilation, hypertension, tonic posturing, B/L 6th nerve palsy, features of midline shift on CT/MRI) * Critically sick (respiratory failure, cardiovascular instability) * Already received albendazole or praziquantel or steroid therapy

Design outcomes

Primary

Measure	Time frame	Description
Number of cyst resolved/ calcified completely after therapy. Resolution or calcification of cyst assessed on CT head at the end of 6 months after starting albendazole	1 year	A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load \< 5

Secondary

Measure	Time frame	Description
Frequency of seizure occurrence	1 year	A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load \< 5
Frequency of occurrence of other symptoms attributable to Neurocysticercosis	1 year	A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load \< 5
Frequency of occurrence of side effects of albendazole	1 year	A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load \< 5

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026